The IC-8® Apthera™ intraocular lens is the first and only small aperture lens for cataract surgery

LAGUNA HILLS, Calif., February 6, 2023 (Newswire.com) - Harvard Eye Associates, a multi-specialty ophthalmology practice, implanted the first IC-8® Apthera™ intraocular lens (IOL) in Orange County, CA, since U.S. FDA approval of this new implant. The Apthera™ lens is the first and only small aperture lens for cataract surgery designed to help patients receive extended depth of focus because of its unique optics. 

The FDA-approved Apthera™ IOL has a FilterRing™ component that creates a small aperture to adjust the amount of light entering the eye. It filters out unfocused light that can cause blurry vision and allows focused light to enter the retina. This provides a continuous range of vision allowing patients to see from near, through intermediate, to distance. 

The Apthera™ IOL is intended for use in one eye with a monofocal or monofocal toric IOL in the fellow eye. This combination is based on the patient's visual needs and can be customized to achieve their best personal results. It has also been shown to help cataract patients that have a low amount of astigmatism (as much as 1.5 diopters).

"This new lens represents a major new offering for people undergoing cataract surgery because it can help them see a range of vision, which previous single-focus were unable to do. Furthermore, this lens may be particularly appropriate for people who have had previous eye surgery like Lasik or RK. It's based on a very simple and well-understood concept from photography--that a small opening in a lens can increase depth of field greatly. Our experience implanting this lens in the studies that led to FDA approval was extremely positive, and we know it will be popular with patients," said Dr. John Hovanesian, one of the board-certified cataract surgeons at Harvard Eye Associates.

Harvard Eye Associates, also an active FDA research center, was involved in the clinical trial of the Apthera™ IOL and has extensive experience with this new lens.

Harvard Eye now offers cataract patients this advanced replacement lens. Patients interested in cataract surgery with the Apthera™ IOL may contact Harvard Eye by calling 949-951-2020 or visiting harvardeye.com.

Contact Information:
Erica Arrington
Marketing & Business Development Manager
[email protected]
(949)900-5228


Original Source: Harvard Eye Associates is the First to Implant the New IC-8® Apthera™ Intraocular Lens in Orange County, CA

The Mullein-X™ Line Consists of Cough^ Syrup, Immune and Relax Cough^ Syrup, and an On-The-Go Throat Soothing Spray. All three formulas include a blend of true 1:1 concentrated herbal extracts formulated utilizing Bio-Chelation® Technology, exclusive to Nature's Answer.

HAUPPAUGE, N.Y., February 6, 2023 (Newswire.com) - Nature's Answer, the company that has been at the forefront of herbal extracts since 1972, has developed a new natural cough syrup, Mullein-X™ Cough Syrup. It's their latest addition to a line of successful natural mullein-based products. 

Nature's Answer Mullein-X™ Cough Syrup is a natural blend of key herbal ingredients that was developed utilizing modern and traditional herbology perfected by Nature's Answer for over 50 years. Mullein-X™ Cough Syrup is formulated to help clear mucus, help soothe the throat and support immune and upper respiratory health.* The exclusive proprietary blend includes herbs such as Mullein, Nettles, Plantain, Elecampane, Horehound and Marshmallow. Many of these herbs are known as soothing demulcents which can support upper respiratory health.*

"And it's not just our new Mullein-X™ Cough Syrup that utilizes this unprecedented combination of ingredients," says Christopher Martir, Manager of Commercial Development & Innovation at Nature's Answer. "All three of our Mullein-X™ products are made from a 1:1 proprietary blend of native herbal extracts historically used as expectorants and demulcents to support immune and upper respiratory health. Achieving this 1:1 blend extraction is a difficult process that requires a unique method created by Nature's Answer called Bio-Chelation®. This proprietary method uses cold extraction to help maintain the natural constituents of the herb, enabling the herb to remain Holistically Balanced™ and for the extract to remain alcohol-free." 

Martir says, "We're proud to say that the Nature's Answer Mullein-X™ line is also the only line of multi-system support formulas that are non-drowsy, alcohol-free, gluten-free, drug-free, preservative-free and contain the exclusive blend of Quik-Sorb®, made from natural ingredients to help aid the body's natural ability to absorb*."

When you look at the ingredients of Mullein-X™ Immune and Relax Support and Mullein-X™ Throat Spray On The Go and the new Mullein-X™Cough Syrup, it's easy to see that they're unlike any other products available today. 

Nature's Answer Mullein-X™ Immune and Relax Support is a natural blend of key herbal ingredients inspired to help support upper respiratory health, immune health and relaxation day or night.* Formulated to help clear mucus with added immune support from Black Elderberry and Zinc.* Unlike typical PM formulas that are designed to put you to sleep, Mullein-X™ is the only multi-system support formula with relaxing herbs like Chamomile, Passion Flower, and the Ayurvedic adaptogen Holy Basil, that will help calm you while providing maximum immune and respiratory support.* 

Nature's Answer Mullein-X™ Throat Spray On The Go is a natural herbal blend inspired and developed to help soothe the throat, clear mucus, and support upper respiratory health.* Unlike typical throat sprays designed to numb the throat, Mullein-X™ On The Go is a powerful throat-soothing blend of Grapefruit Seed Extract, Olive Leaf, Ginger Root, Licorice Root, Slippery Elm Bark, and English Ivy to help soothe irritated throats.* All you have to do is spray the back of your throat and enjoy the soothing power of nature.

"Maintaining the efficacy of our unique formula is just as important as the ingredients that we use," says Dean D'Amelio, "that's why every product in the Mullein-X™ line comes in a glass bottle. Glass packaging is more sustainable and recyclable when compared to plastic packaging."

Product integrity has always been important to Nature's Answer. The company was founded in 1972 by Frank D'Amelio, Sr. and to this day, Nature's Answer remains a family-owned-and-operated business with the highest standards for its natural products and liquid herbal extracts, with uncompromising manufacturing processes perfected over its 50-year history and upheld through three generations of the D'Amelio family still going strong today. This long-term stewardship and personal attention are exceedingly rare in today's natural products marketplace.

As one of America's largest and oldest manufacturers of nutritional supplements, Nature's Answer is an FDA-registered, pharmaceutically licensed herbal manufacturing and quality control facility and has one of the most impressive herbariums in the U.S.

To view all the details of the Nature's Answer Mullein-X™ product line, as well as any of their other natural high-quality products visit the Mullein-X landing page. 

^ For coughs associated with hoarseness, dry throat, and irritants
*This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information:
Kasra Hoshmand
Dir. Brand Marketing
[email protected]
6318403141


Original Source: Nature's Answer Introduces Natural Mullein-X™ Cough^ Syrup to Support a Healthy Respiratory System*

With the voluntary SOC2 certification, Immuware further proves its ongoing commitment to client and software security

CHICAGO, February 6, 2023 (Newswire.com) - Chicago-based Immuware, a software company that specializes in providing hospitals, educational institutions, and other organizations with immunization and illness tracking systems, is proud to announce its recent SOC2 certification. This voluntary compliance standard is another strengthened security investment from the growing software provider and a big step forward in ensuring that clients can safely rely on Immuware to protect their employee health data.

The SOC2 certification was developed by the American Institute of CPAs (AICPA) with the express purpose of specifying guidelines for how organizations should manage customer data. In order to achieve certification, companies must meet strict AICPA guidelines based on the following Trust Services Criteria: security, availability, processing integrity, confidentiality, and privacy.

As a software company, Immuware has long prided itself on providing its clients with an innovative and reliable solution for tracking and managing employee health. And with the new SOC2 certification, the company is able to offer additional peace of mind to clients and further assurance that data will be tracked to the absolute highest industry standards of accuracy and security.

Immuware secure immunization and illness tracking systems help healthcare facilities and other organizations easily compile, assess, and draw reports related to employee vaccination status and general health. And in doing so, the company helps ensure that organizations get increased efficiency where it really counts, with key system features that include real-time reporting, cloud-based data storage, and an easy-to-access health portal for employees.

Upon the announcement of its SOC2 certification, Immuware gets one step closer to establishing itself as a must-have employee health software investment for healthcare facilities, government entities, school systems, energy companies, and more. Organizations that use Immuware achieve compliance 40% faster or more, without worrying that their data is at risk of being compromised. They are also provided with an essential tool for safely storing employee health data in a central location, in turn increasing employee accountability and reducing the risk of data loss.  

Interested readers can find additional information by visiting Immuware's website or contacting the company directly.

About Immuware

Immuware is a software company and consulting firm that provides businesses in the healthcare, energy, education, and government sectors with secure and easy-to-use health-tracking solutions. Immuware applications include innovative vaccination management and illness tracking software, plus streamlined compliance status dashboards that increase accountability and take the guesswork out of identifying compliance gaps.

Please visit www.immuware.com for more information. 

Contact Information:
Alexandria Onwuteaka
Marketing & Sales Coordinator
[email protected]
3125051443


Original Source: Immuware Announces SOC2 Certification as Company Invests in Strengthened Security Measures for Client Health Data

The business is now valued at €62 million following the investment. Medihive includes Ireland's largest online doctor service WebDoctor.ie. The investment will be used to fuel international growth, drive R&D innovation and accelerate healthcare software developments. Medihive will recruit up to 42 key hires across sales, engineering, doctors and marketing departments, adding to the 130 people already working with the company.

DUBLIN, February 6, 2023 (Newswire.com) - Medihive, Ireland's award-winning health technology platform, which includes Webdoctor.ie, has secured an investment from ResMed, an international leader in digital health and cloud-connected medical device innovation, as well as existing shareholders including VentureWave Capital. The investment now values the business at €62 million.

Medihive is a software company built to transform medical processes that don't work so patients can benefit from healthcare that does work. The business provides sophisticated software and clinical solutions to the healthcare, pharmacy and insurance industries, as well as direct to consumers and corporates via www.webdoctor.ie. The company combines digital and clinical know-how to bring clients and their end users high-quality virtual care on a global scale. 

The €7 million investment announced today will be used to further increase the international growth of the business, drive investment and innovation in R&D and accelerate healthcare software developments. The company currently employs 130 people and it is expected this number will now increase by a further 42 employees over the next two years.

ResMed, whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, enabling people to live healthier lives, has been working with Medihive since 2019 and now joins as an investor. ResMed Germany led deal negotiations on behalf of the organisation. As a result of their investment, ResMed will now take a seat on the board to work with the team to accelerate the growth of the business. 

Meanwhile, existing shareholders in Medihive have invested additional capital into the business. This follows the €3 million investment in August 2021 by VentureWave Capital, the private equity firm that focuses on entrepreneurial companies that make a positive social impact, are in vital sectors and address UN Sustainable Development Goals. At the time of VentureWave Capital's €3 million in August 2021, the business was valued at €48 million. Today's investment now values the company at €62 million, a significant 29% increase.

Noel McSweeney, Chairman of Medihive, said: "The investment from ResMed alongside the increased support from current shareholders demonstrates our shared passion for medical technology advancement and will allow Medihive and Webdoctor.ie to further expand and develop our services while continuing to provide transformative digital healthcare solutions."

Katrin Pucknat, President of ResMed Germany, said: "At ResMed, our mission is to change 250 million lives in 2025 in out-of-hospital care settings, and today's announcement fits perfectly with that goal. Our work to date with Medihive has transformed the lives of our patients by making their care pathway less disjointed and allowing them to get diagnosed for sleep apnea outside of a hospital setting. ResMed places significant importance on innovation and this investment will enable both organisations to continue to be at the forefront of developments in healthcare technology. We look forward to supporting the team at Medihive as part of their board and believe this relationship will create new opportunities for us both while continuing to transform the healthcare industry."

David Crimmins, CEO of MediHive, said: "Medihive builds solutions to deliver positive patient outcomes by removing friction from their care journeys. This investment now comes at a pivotal moment for Medihive. Over the last two and a half years, demand for our services has surged as organisations realised they can achieve better patient outcomes by blending smart health technology with their traditional health infrastructures. This investment will enable us to continue meeting this demand while also allowing us to scale and expand our services in the continually evolving telehealth market both in Ireland and internationally. It's an exciting time for Medihive, and we're really looking forward to working with ResMed and our current shareholders to continue to make advances and improvements in digital healthcare for patients and professionals in the industry alike."

Alan Foy, Chairman and Managing Partner VentureWave Capital, said: "We are delighted to once again invest in Medihive alongside ResMed, a key strategic investor. As a successful Irish health technology business that's making an impact on delivering digital health and patient outcomes, this investment demonstrates our continued support and confidence in Medihive's business goals, global impact and strategic ambitions."

                       Inspiring a world where instant, frictionless access to healthcare is the norm.

                                                             Medihive, Welcome Tomorrow.

For more information, visit www.medihive.com

Contact Information:
Breda Brown
PR Director
[email protected]
087 2487120

Viv Murphy
PR Senior Account Manager
[email protected]
0876160846
Related Files
Authorization_Form.pdf

Related Images


Original Source: Irish MedTech Company Medihive Receives €7 Million Investment

GEORGETOWN, Ky., February 6, 2023 (Newswire.com) - Ananda Professional's multimillion-dollar research program continues to lead the way in identifying novel ways to leverage cannabinoids for the broad benefits they deliver for health and longevity. A breakthrough in the research and formulation has resulted in Ananda transcending beyond the 'CBD' category and delivering an innovative range of products focused on patient outcomes with results patients can feel.   

Dr. Alex Capano, who leads Ananda Professional's research and cannabinoid formulation, said, "We've always known about the importance of entourage effect - that the benefit of the whole spectrum of hemp-derived cannabinoids and terpenes is greater than the sum of its parts. Now we've been able to carefully select and control the dosages of these important emerging phytochemicals into this new breakthrough range."

InflaEze™ is formulated for natural, soothing relief with a combination of CBD, CBD-a, CBC, THC and terpenes.

SomniVive™ targets a better night's sleep with CBD, CBN and THC.

SereniPlex™ is designed to help patients relax and unwind with a selection of CBD, CBG, CBN, THC and terpenes 

Phase two and three will expand the assortment over the coming months with multi-active softgel and gummy formulations for enhanced efficacy and compliance.  All formulations were developed by Ananda Professional's Chief Science Officer, Dr. Alex Capano, and newly appointed Chief Marketing Officer Neal Mercado.   

About Ananda Professional: Since 2018, Ananda Professional has been a pioneer in the hemp and CBD industry, with a core focus on improving patient outcomes through professional healthcare channels. Top-quality seed genetics, a team of clinical formulators and a state-of-the-art production facility make Ananda Professional the most trusted brand of practitioners, pharmacists, and patients.

Contact Information:
Chris Lee
Brand Director - Ananda Professional
[email protected]
888-388-1119


Original Source: No Longer Just CBD - Ananda Professional Re-Writes the Category With Its New Condition-Driven Minor Cannabinoid Range

NEW YORK, February 6, 2023 (Newswire.com) - Oculogica Inc. announces publication of the initial five-site study performed to obtain FDA Marketing Authorization for its EyeBOX technology as an aid in the diagnosis of concussion. EyeBOX uses eye tracking to assess pupil size and position to determine whether a person has sustained damage to brain regions that control those functions.

The study, published in Frontiers in Neurology Dec. 1, 2022, was performed on 282 emergency room or concussion clinic patients ages 5 to 67 within two weeks of injury. Study participants were evaluated at New York City's Bellevue Hospital, Rochester's Mayo Clinic, Pittsburgh's Allegheny Hospital, Denver's Rocky Mountain Hospital for Children, and Beaver Dam Wisconsin's Community Hospital.

The study demonstrated that patients who had symptoms of concussion and scored poorly on a cognition assessment were more likely to have abnormal eye tracking, as assessed by the technology's proprietary BOX (Brain injury associated Ocular motility dysfunction) Score. The BOX Score diagnosed concussion with over 80% sensitivity.

"The brain has tremendous heterogeneity of normal baseline function. This makes it challenging to figure out normal versus abnormal function when injury occurs. Assessment of pupil size and movement can be a powerful way to assess function because the majority of people have relatively normal function that is controlled reflexively. A person cannot pretend to have pupils that constrict normally and move in a synchronized way when they do not," said neurosurgeon Uzma Samadani, MD, Ph.D., and Oculogica founder. "Similarly, if their brain and therefore pupil function is normal, it is difficult to pretend that it is not. Eye tracking to assess pupil size and position is a truly objective measure of physiologic brain function. We consider it a form of more precise digital neurologic examination. We believe that this will eventually and inevitably become standard of care."

"We decided to publish this data because so many people have asked us what the gold-standard for concussion is, and how one obtains FDA approval for a concussion diagnostic," said Oculogica CEO Rosina Samadani, Ph.D. "The reality is that there is currently no single gold-standard, and that is one of the challenges of any study in the field. We found that those with the worst symptoms and poorest cognition were most likely to have an elevated BOX score. Fundamentally, if a patient has abnormal eye reflexes or movement, that is their objective physiologic condition, regardless of symptom severity or ability to perform on a cognitive test. This information is helpful when people may under or over-report symptoms or have high or low baseline cognitive skills. It also may reduce biases due to language, culture, education or other factors that impact traditional patient assessment."

The EyeBOX technology is the first non-invasive, non-baseline requiring concussion diagnostic approved by the FDA for aid in the diagnosis of concussion. Leading clinics, such as the Mayo Clinic, Midwest Orthopedics at Rush University and Minneapolis Clinic of Neurology, amongst others, offer the technology.

Contact Information:
Cady Roedl
Customer Success Manager
[email protected]
9205173873


Original Source: Oculogica Publishes 5-Site Study on Its FDA-Cleared Concussion Diagnostic

The new digital workers are designed to automate the inbound shipping process, accounts payable processing, delinquent invoices, and tax cards and vesting deeds.

EDISON, N.J., February 6, 2023 (Newswire.com) - Intelligent Automation Platform OpenBots is collaborating with three solutions providers, Xpertek Contact, Roth Automation, and Intellese, to develop four new digital assistants for its growing digital workforce. 

OpenBots is a fully bundled intelligent automation platform that allows companies to scale their digital transformation initiatives. Until now, businesses had to pay expensive licensing fees. OpenBots flips the script by giving companies access to its complete line of enterprise tools with monthly plans based on consumption hours instead of individual automation. 

Xpertek Contact offers services and solutions in hyperautomation, electronic data extraction, and Wi-Fi Location-based marketing. The company is the developer of digital assistants Rachel and Fred. Rachel is an inbound shipping process assistant that automates the inbound shipping process to enable online retailers to receive orders in their warehouses much faster. The result is a faster turnaround on customer orders. Fred provides 80% faster invoice or payment approval times, 100 reductions in paper documents, and 100% accuracy between Purchase Order and ERP. 

Intellese is a consultant company in the energy sector. They provide an automation solution is a Tax Card and Vesting Deeds digital assistant used to simplify the process for land agents to get ownership information, land information, and taxation information to determine who owns a property, what they are doing with the property, the value of the property, and the location of the property.   

Vesting Deeds show how and when a person or entity acquired a piece of real property. Landmen, Abstractors, and Title Attorneys need this information to begin chaining titles back 20, 50, or 100 years, or all the way back to sovereignty. Sadly, these processes are very tedious and time-consuming; however, with this new digital assistant, land agents can focus on more involved tasks such as chaining titles, looking for encumbrances and liabilities, and organizing the data, while Intellise's digital worker quickly finds and extracts the data they need. In comparison, human agents save the file up to 75% faster and can run at the beginning of the project in bulk so that the entire data set is ready for access simultaneously.     

Roth Automation is a provider of end-to-end professional services and project management. The company offers a range of solutions to capture, extract and utilize information from documents to automate repetitive, error-prone work processes to amplify efficiency. Roth Automation designed XO to automate the collection of delinquent invoices. XO follows all the same processes as a human worker but at a much faster pace and with greater accuracy.  

For further information visit: https://openbots.ai/digital-workers 

Contact Information:
Jason Dzamba
Director of Media Relations
[email protected]
1-646-216-7541


Original Source: OpenBots Expands Network to Include Xpertek Contact, Roth Automation, and Intellese Digital Worker Solutions